<DOC>
	<DOCNO>NCT02629718</DOCNO>
	<brief_summary>To clarify potential benefit NACT radical surgery ( RS ) , perform phase III , randomise control trial compare NACT plus RS RS alone patient stage IB2 IIA2 cervical cancer .</brief_summary>
	<brief_title>Neoadjuvant Chemotherapy + Surgery Versus Surgery FIGO IB2 IIA2 Cervical Cancer</brief_title>
	<detailed_description>Patients International Federation Gynecology Obstetrics ( FIGO ) stage IB2 IIA2 cervical cancer eligible study . They receive paclitaxel + cisplatin ( TP ) /carboplatin ( TC ) regimen neoadjuvant chemotherapy ( NACT ) 3 cycle follow radical surgery ( RS ) ( type III V radical hysterectomy plus systematic pelvic lymphadenectomy ) ( arm A ) directly radical surgery ( arm B ) . Postoperative pelvic radiotherapy start within 6 week surgery patient pelvic lymph node metastasis , parametrial involvement , deep stromal invasion positive margin . Extended-field external beam therapy , deliver dose 4500cGy four-field technique , administer patient positive para-aortic node . High-dose rate brachytherapy deliver vaginal stump patient positive surgical margin . The primary end point 2-years progression-free survival , The secondary end point overall survival , rate response TP TC regimen chemotherapy quality life .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Patients newly histologically confirm cervical carcinoma ; Histopathology squamaous carcinoma , adenocarcinoma adenosquamous carcinoma ; Original clinical stage must IB2 IIA2 （FIGO ) ; Age 1865 ; Patients must give sign informed consent ; P.S status : 01 ; Estimated survival time ＞ 3 month ; The presence uncontrolled lifethreatening illness ; Receiving way anticancer therapy ; Investigator consider patient ca n't finish whole study ; With normal liver function test ( ALT、AST &gt; 2.5×ULN ) ; With normal renal function test ( Creatinine &gt; 1.5×ULN ) ; WBC &lt; 4,000/mm3 PLT &lt; 100,000/mm ; Accompany malignancy .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>neoadjuvant chemotherapy</keyword>
	<keyword>radical surgery</keyword>
	<keyword>cervical carcinoma</keyword>
</DOC>